Mandelcorn Efrem D, Palestine Alan G, Dubovy Sandor, Davis Janet L
J Ophthalmic Inflamm Infect. 2010 Nov 17;1(1):35-8. doi: 10.1007/s12348-010-0013-7.
Chemotherapy with bevacizumab alters the angiogenic environment, and therefore, the growth and spread of metastases. We present a patient with metastatic lung adenocarcinoma to the eye with findings suggestive of retinal vascular co-option.
Case report.
A 57-year-old male, receiving systemic bevacizumab for metastatic lung adenocarcinoma, presented with vitreous opacities and clumped deposits adherent to the retinal vessels. No choroidal metastases were present. Diagnostic vitrectomy yielded cellular evidence of adenocarcinoma, with thyroid transcription factor-1 staining confirming a lung primary.
The perivascular growth of small foci of metastatic vitreous cells suggests vascular co-option from the native retinal circulation. Similar modification of metastatic disease by bevacizumab has been observed in animal models and selected human cases.
使用贝伐单抗进行化疗会改变血管生成环境,进而影响转移灶的生长和扩散。我们报告一例转移性肺腺癌累及眼部的患者,其表现提示视网膜血管共选择现象。
病例报告。
一名57岁男性,因转移性肺腺癌接受全身贝伐单抗治疗,出现玻璃体混浊及附着于视网膜血管的团块状沉积物。未发现脉络膜转移。诊断性玻璃体切除术获得了腺癌的细胞证据,甲状腺转录因子-1染色证实原发于肺。
转移性玻璃体细胞小灶的血管周围生长提示源自视网膜自身循环的血管共选择。在动物模型和部分人类病例中也观察到贝伐单抗对转移性疾病有类似的作用。